Bifogade filer
LIFE: Final purchase order for automated production components - micro-fluidic handling and dispensing devices
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Bergen, Norway, December 13th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that yet an additional preparational step for the Company’s automated production has been met as Lifecare has placed the purchase order for a BioScaffolder (“BS 3.3) and a customized Nano-Plotter (“NP 2.1”) from the German supplier GeSiM mbH.
This purchase order is in alignment with Lifecare’s planned progress roadmap towards automated production by end of Q2 2024, and consequently product launch in the veterinary marked. With reference to Lifecare’s previous market communication (stock exchange notifications November 20th and 28th, 2023), the order of BS 3.3 and NP 2.1 concludes the Company’s plan to order production equipment for automated production in Q4 2023. Lifecare can now successfully conclude the roadmap progress as presented at the Company’s semi-annual report of August 20th, 2023, and later investor communication.
The BS 3.3 and NP 2.1 will be essential tools for the automated process of filling Lifecare’s proprietary and patented glucose-reactive chemical solution in the nanosized chambers of the sensors, as well as applying the nano-porous membranes to seal the chambers after filling.
FINAL MAJOR PURCHASE ORDER
During the past year, Lifecare has carried out the necessary studies and experiments that prove the Sencell sensor's sensitivity and longevity. Quality management systems have been established through compliance with ISO 9001 and ISO 13485 and the company has recruited highly qualified key personnel for production preparations. Placing this purchase order concludes Lifecare’s core preparations to reach the goals to initiate pilot production in Q1 and automated production Q2 2024.
- Following the successful conclusion of our clinical study in May 2023, the whole organization has worked focused on production preparations, and we have achieved a number of important technical and practical milestones. While some achievements might seem of minor importance on an individual base, the totality of our achievements and preparations in 2023 are nothing less than amazing, says CEO Joacim Holter at Lifecare.
- This is our final major investment of production equipment related to the automated production. We are now ready to start 2024 better prepared than ever, with a firm confidence that production and market launch is within reach, says Holter.
******
For reference purposes; https://lifecare.no/news/information-from-lifecare-april-2022/
******